HEALTH● LOW22h ago · Oct 24, 2026, 2:30 AM
Moderna - Merck personalized mRNA melanoma vaccine cuts relapse risk in late - stage trial
local21news.com · United States · global
A personalized mRNA melanoma vaccine developed by Moderna and Merck has shown to cut relapse risk in a late-stage trial. This represents a promising advancement in cancer treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
See it on the live mapUnited States and nearby eventsMore from United StatesLatest stories and threat level
More from United States
POLITICS1h agoCountdown to the United States elections: Donald Trump and Melania voted earlyClarínPOLITICS5h agoALÇUFROM : What the United States gets wrong about France student protests - The Cavalier Daily - University of Virginia Student Newspapercavalierdaily.com · United StatesWORLD11h agoLionel Messi's frantic 72 hours: after revolutionizing Oviedo and receiving the Princess of Asturias, he flew to the United States and plays today for the MLSClarínWORLD14h agoThe prestigious ocean liner SS United States will sink to the bottom of Florida to become a natural reef for hundreds of marine speciesClarín
More in Health
HEALTH53m agoAlert in a Mendoza hospital: two patients died from a bacterial infection after surgeryClarínHEALTH1h agoWoman whose cancer was almost missed wants breast density reporting in screeningrnz.co.nzHEALTH2h agoMeet the volunteers helping adults navigate their healthCBS NewsHEALTH2h agoDr . Samuel Esterson : Suburban Orthodox Toras Chaim Retiree Providing Medical Care in Israeljewishtimes.com · United States